Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05332925 · ClinicalTrials.gov registry record
Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC
A clinical trial of Lung Cancer and NSCLC, sponsored by Jun Zhang, MD, PhD.
- Recruiting
- Registry status
- 25
- Enrollment target
- 2
- Study locations
NCT05332925 is a study of Lung Cancer and NSCLC that is actively recruiting participants, run by Jun Zhang, MD, PhD. The registered enrollment target is 25 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05332925, a study of Lung Cancer and NSCLC, is actively recruiting participants, sponsored by Jun Zhang, MD, PhD.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
Conditions Studied
Interventions
- DRUG Standard of care immune checkpoint inhbitors
Study Locations (2)
Kansas
- The University of Kansas Cancer Center (KUCC) - Fairway
- The University of Kansas Cancer Center, Westwood Campus - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2027-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05332925
The ClinicalTrials.gov registry entry for NCT05332925 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Jun Zhang, MD, PhD, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Standard of care immune checkpoint inhbitors is the first listed.
NCT05332925 reports 2 study locations spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT05332925 about?
NCT05332925 is a clinical study titled "Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC". To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.
What is the current status of trial NCT05332925?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2022-07-21. Estimated completion is 2027-02.
What conditions does trial NCT05332925 study?
This clinical trial studies the following conditions: Lung Cancer, NSCLC, NSCLC Stage IV.
What interventions are being tested in trial NCT05332925?
The interventions under investigation include: Standard of care immune checkpoint inhbitors (DRUG).
Who is sponsoring clinical trial NCT05332925?
This trial is sponsored by Jun Zhang, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05332925 being conducted?
This trial has 2 study locations across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.